Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Share-based Compensation (2016 - 2025)

Cytosorbents (CTSO) has disclosed Share-based Compensation for 14 consecutive years, with $488000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 45.23% year-over-year to $488000.0, compared with a TTM value of $2.8 million through Sep 2025, down 35.63%, and an annual FY2024 reading of $3.8 million, down 9.53% over the prior year.
  • Share-based Compensation was $488000.0 for Q3 2025 at Cytosorbents, down from $572574.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.7 million in Q4 2023 and bottomed at $488000.0 in Q3 2025.
  • Average Share-based Compensation over 5 years is $898811.7, with a median of $830000.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 113.59% in 2021, then crashed 49.46% in 2022.
  • Year by year, Share-based Compensation stood at $796564.0 in 2021, then increased by 9.16% to $869517.0 in 2022, then surged by 91.87% to $1.7 million in 2023, then tumbled by 44.88% to $919534.0 in 2024, then crashed by 46.93% to $488000.0 in 2025.
  • Business Quant data shows Share-based Compensation for CTSO at $488000.0 in Q3 2025, $572574.0 in Q2 2025, and $818426.0 in Q1 2025.